Last updated: March 13, 2026
What is the Current Status of NDC 31722-0168?
NDC 31722-0168 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis indicated for spinal muscular atrophy (SMA) in pediatric patients under the age of two. Approved by the FDA in May 2019, Zolgensma is the only gene therapy approved for SMA and has a pricing model reflecting its one-time administration.
Market Environment
Patient Population
- Estimated SMA incidence: 1 in 10,000 live births globally.
- U.S. pediatric SMA population: approximately 400 to 600 patients eligible annually.
- Market penetration: Early adoption in the U.S. exceeds 60%; growth depends on expanded indications.
Competitive Landscape
- Prevailing Treatment Options:
- Spinraza (nusinersen): Intrathecal antisense oligonucleotide, approved in 2016.
- Evrysdi (risdiplam): Oral medication, approved in 2020.
- Zolgensma's unique off-the-shelf gene therapy; advantages include a single dose and potential durability.
Reimbursement Trends
- United States: Medicare and private insurers generally reimburse at or near list price.
- International markets: Reimbursement varies, with some countries negotiating discounted prices—typically 25-50% below U.S. list prices.
Price History and Current Valuation
- Initial list price: $2.125 million per dose (2019).
- Industry standard discounting: Insurers and PBMs negotiate discounts; estimated net price per dose ranges from $1.5 million to $1.9 million.
- Pricing factors: Sale prices depend on negotiated discounts, rebate contracts, and patient assistance programs.
Market Projections
Short-term (1-3 years)
- Demand growth: Expected to increase as approval expands to older SMA patients and other indications.
- Price stability: Likely to remain near current levels due to limited competition and high treatment efficacy.
- Market penetration: Could reach 70%-80% among eligible patients in the U.S.
Medium-term (3-5 years)
- Introduction of biosimilar or similar gene therapies: Unlikely within this timeframe, maintaining Novartis's market dominance.
- Regulatory approvals: Anticipated for additional indications or expanded age ranges, opening new patient segments.
Long-term (5+ years)
- Potential price reductions: May occur through manufacturing efficiencies, market saturation, or competing therapies.
- Market size: Expected to plateau as the treatable patient population reaches near-maximum penetration.
Price Projections
| Year |
Estimated Price Range (Net) |
Key Factors |
| 2023 |
$1.6M - $1.8M |
Stable demand, no significant competition |
| 2025 |
$1.5M - $1.7M |
Slight discounts, expanded indications |
| 2030 |
$1.4M - $1.6M |
Market saturation, potential competition |
Key Market Dynamics
- Pricing pressure will likely remain muted in the near term due to the therapy’s curative potential and limited competition.
- Reimbursement negotiations influence actual transaction prices, with certain payers securing discounts.
- Manufacturing costs for gene therapies have historically decreased modestly but are unlikely to significantly affect pricing within the forecast horizon.
Regulatory and Policy Considerations
- USA: Price negotiations and rebate programs influence net prices.
- Europe and Asia: Price control policies may drive lower prices; some countries restrict maximum prices for orphan drugs.
- Policies favoring value-based pricing could compress prices further as data on long-term efficacy and safety accrues.
Conclusion
Zolgensma (NDC 31722-0168) maintains one of the highest drug prices in the biotech space, with current net prices around $1.6 million per dose. Demand is expected to rise, but prices are unlikely to decrease substantially in the short to medium term. Market growth depends heavily on approved indications, reimbursement strategies, and emerging competitors.
Key Takeaways
- Zolgensma's high price primarily reflects its curative potential and single-dose administration.
- Pricing stability is expected over the next 3-5 years, with potential modest declines driven by market saturation and policy changes.
- Expanding indications and international access will influence revenue streams.
- Competitive threats remain limited in the near term but could impact long-term pricing.
- Reimbursement negotiations continue to play a critical role in determining actual sale prices.
FAQs
Q1: What factors influence the negotiated price of Zolgensma?
A1: Reimbursement negotiations, manufacturer discounts, rebate agreements, and patient assistance programs.
Q2: Are there any emerging competitors to Zolgensma?
A2: No direct gene therapy competitors are approved yet; however, other SMA treatments like Spinraza and Evrysdi remain significant. Future competitors could emerge with new gene therapies.
Q3: How does international reimbursement policy affect Zolgensma pricing?
A3: Countries with price controls or tight drug budgets may negotiate substantially lower prices, often 25-50% below U.S. list prices.
Q4: What is the long-term outlook for Zolgensma pricing?
A4: Prices are expected to remain high but may decline gradually due to market saturation, manufacturing efficiencies and policy changes.
Q5: How does expanding age indications affect the market?
A5: It allows access to a broader patient population, increasing revenue but potentially affecting pricing negotiations as the treatment expands beyond the initial target group.
References
[1] Food and Drug Administration. (2019). FDA approves gene therapy for spinal muscular atrophy. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm635201.htm
[2] Novartis. (2019). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/zolgensma.pdf
[3] IQVIA. (2022). U.S. Biotech Market Insights.
[4] World Health Organization. (2021). Global prevalence of SMA. https://www.who.int/publications/i/item/9789240024320
[5] EvaluatePharma. (2022). 10-Year Forecast for Rare Disease Therapies.
